Trials / Completed
CompletedNCT02860780
A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
A Phase 1 Dose-Escalation Study of LY2606368 in Combination With Ralimetinib in Patients With Advanced or Metastatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | prexasertib | Administered IV |
| DRUG | ralimetinib | Administered orally |
Timeline
- Start date
- 2016-08-10
- Primary completion
- 2017-05-15
- Completion
- 2017-05-15
- First posted
- 2016-08-09
- Last updated
- 2018-12-14
Locations
3 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT02860780. Inclusion in this directory is not an endorsement.